메뉴 건너뛰기




Volumn 55, Issue , 2004, Pages 505-518

Botulinum toxin and other new approaches to migraine therapy

Author keywords

Angiotensin blockers; Antinociception; Headache; Prevention; Topiramate

Indexed keywords

ACETYLCHOLINE; AMINOGLYCOSIDE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEUROTOXIN; TOPIRAMATE;

EID: 1542329006     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.55.091902.104440     Document Type: Review
Times cited : (29)

References (85)
  • 3
    • 0036850282 scopus 로고    scopus 로고
    • Botulinum and tetanus neurotoxins: Structure, function and therapeutic utility
    • Turton K, Chaddock JA, Acharya KR. 2002. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem. Sci. 27:552-58
    • (2002) Trends Biochem. Sci. , vol.27 , pp. 552-558
    • Turton, K.1    Chaddock, J.A.2    Acharya, K.R.3
  • 4
    • 33748271738 scopus 로고    scopus 로고
    • Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology
    • Brin MF. 1997. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 20:S146-S168
    • (1997) Muscle Nerve , vol.20
    • Brin, M.F.1
  • 5
    • 0032145932 scopus 로고    scopus 로고
    • Botulism in the United States: A clinical and epidemiologic review
    • Shapiro RL, Hatheway C, Swerdlow DL. 1998. Botulism in the United States: a clinical and epidemiologic review. Ann. Intern. Med. 129:221-28
    • (1998) Ann. Intern. Med. , vol.129 , pp. 221-228
    • Shapiro, R.L.1    Hatheway, C.2    Swerdlow, D.L.3
  • 6
    • 0025857556 scopus 로고
    • Therapeutic uses of botulinum toxin
    • Jankovic J, Brin MF. 1991. Therapeutic uses of botulinum toxin. N. Engl. J. Med. 324:1186-94
    • (1991) N. Engl. J. Med. , vol.324 , pp. 1186-1194
    • Jankovic, J.1    Brin, M.F.2
  • 7
    • 0000810225 scopus 로고    scopus 로고
    • Botulinum toxin: Historical perspective and potential new indications
    • Jankovic J, Brin ME. 1997. Botulinum toxin: historical perspective and potential new indications. Muscle Nerve 20:S129-S145
    • (1997) Muscle Nerve , vol.20
    • Jankovic, J.1    Brin, M.E.2
  • 8
    • 0034758711 scopus 로고    scopus 로고
    • Review of botulinum toxin type a and its clinical applications in migraine headache
    • Silberstein SD. 2001. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin. Pharmacother. 2:1649-54
    • (2001) Expert Opin. Pharmacother. , vol.2 , pp. 1649-1654
    • Silberstein, S.D.1
  • 9
    • 0036841338 scopus 로고    scopus 로고
    • Considering the immune response to botulinum toxin
    • Critchfield J. 2002. Considering the immune response to botulinum toxin. Clin. J. Pain 18:S133-S141
    • (2002) Clin. J. Pain , vol.18
    • Critchfield, J.1
  • 10
    • 0029977787 scopus 로고    scopus 로고
    • Botulinum toxin therapy, immunologic resistance, and problems with available materials
    • Borodic G, Johnson E, Goodnough M, et al. 1996. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 46:26-29
    • (1996) Neurology , vol.46 , pp. 26-29
    • Borodic, G.1    Johnson, E.2    Goodnough, M.3
  • 11
    • 0031955695 scopus 로고    scopus 로고
    • Current concepts on the clinical features, aetioogy and management of idiopathic cervical dystonia
    • Dauer WT, Burke RE, Greene P, et al. 1998. Current concepts on the clinical features, aetioogy and management of idiopathic cervical dystonia. Brain 121:547-60
    • (1998) Brain , vol.121 , pp. 547-560
    • Dauer, W.T.1    Burke, R.E.2    Greene, P.3
  • 12
    • 0027421580 scopus 로고
    • Botulinum antibodies in dystonic patients treated with type a botulinum toxin: Frequency and significance
    • Zuber M, Sebald M, Bathien N, et al. 1995. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 43:1715-18
    • (1995) Neurology , vol.43 , pp. 1715-1718
    • Zuber, M.1    Sebald, M.2    Bathien, N.3
  • 13
    • 0028345811 scopus 로고
    • Development of resistance to botulinum toxin type a in patients with torticollis
    • Greene P, Fahn S, Diamond B. 1994. Development of resistance to botulinum toxin type A in patients with torticollis. Mov. Disord. 9:213-17
    • (1994) Mov. Disord. , vol.9 , pp. 213-217
    • Greene, P.1    Fahn, S.2    Diamond, B.3
  • 14
    • 0028803612 scopus 로고
    • Response and immunoresistance to botulinum toxin injections
    • Jankovic J, Schwartz K. 1995. Response and immunoresistance to botulinum toxin injections. Neurology 45:1743-46
    • (1995) Neurology , vol.45 , pp. 1743-1746
    • Jankovic, J.1    Schwartz, K.2
  • 15
    • 1542276451 scopus 로고    scopus 로고
    • Botulinum toxin type B in antibody-induced botulinum toxin type a therapy failure
    • Abstr.
    • Dressler DW, Bigalke H, Benecke R. 2003. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. Neurology 60:A465-A466 (Abstr.)
    • (2003) Neurology , vol.60
    • Dressler, D.W.1    Bigalke, H.2    Benecke, R.3
  • 16
    • 26144434854 scopus 로고    scopus 로고
    • Development of a new low molecular weight botulinum type a neurotoxin preparation for treating muscle hyperactivity
    • Abstr.
    • Sakamoto T, Asanuma K, Kaji R, et al. 2003. Development of a new low molecular weight botulinum type A neurotoxin preparation for treating muscle hyperactivity. Neurology 60:A466 (Abstr.)
    • (2003) Neurology , vol.60
    • Sakamoto, T.1    Asanuma, K.2    Kaji, R.3
  • 17
    • 0035076007 scopus 로고    scopus 로고
    • Pharmacology and immunology of botulinum toxin serotypes
    • Aoki KR. 2001. Pharmacology and immunology of botulinum toxin serotypes. J. Neurol. 248:3-10
    • (2001) J. Neurol. , vol.248 , pp. 3-10
    • Aoki, K.R.1
  • 18
    • 0032839760 scopus 로고    scopus 로고
    • Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system
    • Naumann M, Jost WH, Toyka KV. 1999. Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system. Arch. Neurol. 56:914-16
    • (1999) Arch. Neurol. , vol.56 , pp. 914-916
    • Naumann, M.1    Jost, W.H.2    Toyka, K.V.3
  • 19
    • 0035864927 scopus 로고    scopus 로고
    • Botulinum toxin a for axillary hyperhidrosis (excessive sweating)
    • Heckmann M, Ceballos-Baumann AO, Plewig G, for the Hyperhidrosis Study Group. 2001. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N. Engl. J. Med. 344:488-93
    • (2001) N. Engl. J. Med. , vol.344 , pp. 488-493
    • Heckmann, M.1    Ceballos-Baumann, A.O.2    Plewig, G.3
  • 20
    • 0030710177 scopus 로고    scopus 로고
    • The mechanism of action of botulinum toxin type a in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injection site
    • Giladi N. 1997. The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injection site. J. Neurol. Sci. 152:123-35
    • (1997) J. Neurol. Sci. , vol.152 , pp. 123-135
    • Giladi, N.1
  • 21
    • 0027312028 scopus 로고
    • Botulinum a toxin effects on rat jaw muscle spindles
    • Filippi GM, Errico P, Santarelli R, et al. 1993. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol. 113:400-4
    • (1993) Acta Otolaryngol. , vol.113 , pp. 400-404
    • Filippi, G.M.1    Errico, P.2    Santarelli, R.3
  • 22
    • 0029920995 scopus 로고    scopus 로고
    • Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection
    • Resales RL, Arimura K, Takenaga S, et al. 1996. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 19:488-96
    • (1996) Muscle Nerve , vol.19 , pp. 488-496
    • Resales, R.L.1    Arimura, K.2    Takenaga, S.3
  • 23
    • 0033916697 scopus 로고    scopus 로고
    • How does botulinum toxin work?
    • Hallett M. 2000. How does botulinum toxin work? Ann. Neurol. 48:7-8
    • (2000) Ann. Neurol. , vol.48 , pp. 7-8
    • Hallett, M.1
  • 24
    • 0017701735 scopus 로고
    • The action of botulinum a neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex
    • Wiegand H, Wellhoner HH. 1977. The action of botulinum A neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex. Naunyn Schmiedebergs Arch. Pharmacol. 298:235-38
    • (1977) Naunyn Schmiedebergs Arch. Pharmacol. , vol.298 , pp. 235-238
    • Wiegand, H.1    Wellhoner, H.H.2
  • 25
    • 0031731126 scopus 로고    scopus 로고
    • The development of BOTOX - Its history and pharmacology
    • Aoki R. 1998. The development of BOTOX - its history and pharmacology. Pain Digest 8:337-41
    • (1998) Pain Digest , vol.8 , pp. 337-341
    • Aoki, R.1
  • 26
    • 0020592243 scopus 로고
    • Tetanus and botulinum toxins inhibit, and black widow spider venom stimulates the release of methionine-enkephalin-like material in vitro
    • Janicki PK, Habermann E. 1983. Tetanus and botulinum toxins inhibit, and black widow spider venom stimulates the release of methionine-enkephalin-like material in vitro. J. Neurochem. 41:395-402
    • (1983) J. Neurochem. , vol.41 , pp. 395-402
    • Janicki, P.K.1    Habermann, E.2
  • 27
    • 0031919375 scopus 로고    scopus 로고
    • The corticomotor representation of upper limb muscles in writer's cramp and changes following botulinum toxin injection
    • Byrnes ML, Thickbroom GW, Wilson SA, et al. 1998. The corticomotor representation of upper limb muscles in writer's cramp and changes following botulinum toxin injection. Brain 121:977-88
    • (1998) Brain , vol.121 , pp. 977-988
    • Byrnes, M.L.1    Thickbroom, G.W.2    Wilson, S.A.3
  • 28
    • 0033945711 scopus 로고    scopus 로고
    • Effects of botulinum toxin type a on intracortical inhibition in patients with dystonia
    • Gilio F, Currà A, Lorenzano C, et al. 2000. Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia. Ann. Neurol. 48:20-26
    • (2000) Ann. Neurol. , vol.48 , pp. 20-26
    • Gilio, F.1    Currà, A.2    Lorenzano, C.3
  • 29
    • 0035085437 scopus 로고    scopus 로고
    • Botulinum toxin a in the treatment of headache syndromes and pericranial pain syndromes
    • Gobel H, Heinze A, Kuhn KH, et al. 2001. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain 91:195-99
    • (2001) Pain , vol.91 , pp. 195-199
    • Gobel, H.1    Heinze, A.2    Kuhn, K.H.3
  • 30
    • 0034895356 scopus 로고    scopus 로고
    • Botulinum toxin therapy for pain and inflammatory disorders: Mechanisms and therapeutic effects
    • Borodic GE, Acquadro M, Johnson EA. 2001. Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin. Investig. Drugs 10:1531-44
    • (2001) Expert Opin. Investig. Drugs , vol.10 , pp. 1531-1544
    • Borodic, G.E.1    Acquadro, M.2    Johnson, E.A.3
  • 31
    • 0036840904 scopus 로고    scopus 로고
    • Possible mechanisms for the effects of botulinum toxin on pain
    • Arezzo JC. 2002. Possible mechanisms for the effects of botulinum toxin on pain. Clin. J. Pain 18:S125-S132
    • (2002) Clin. J. Pain , vol.18
    • Arezzo, J.C.1
  • 32
    • 0000099458 scopus 로고    scopus 로고
    • Botulinum toxin type a (BTX-A) reduces inflammatory pain in the rat formalin model
    • Cui M, Aoki KR. 2000. Botulinum toxin type A (BTX-A) reduces inflammatory pain in the rat formalin model. Cephalalgia 20:414
    • (2000) Cephalalgia , vol.20 , pp. 414
    • Cui, M.1    Aoki, K.R.2
  • 33
    • 0030853667 scopus 로고    scopus 로고
    • Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia
    • Lew MF, Adornato BT, Duane D, et al. 1997. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 49:701-7
    • (1997) Neurology , vol.49 , pp. 701-707
    • Lew, M.F.1    Adornato, B.T.2    Duane, D.3
  • 34
    • 0037322405 scopus 로고    scopus 로고
    • Botulinum toxin a reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin
    • Kramer HH, Angerer C, Erbguth F, et al. 2003. Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J. Neurol. 250:188-93
    • (2003) J. Neurol. , vol.250 , pp. 188-193
    • Kramer, H.H.1    Angerer, C.2    Erbguth, F.3
  • 35
    • 0037116179 scopus 로고    scopus 로고
    • Botulinum toxin a and the cutaneous nociception in humans: A prospective, double-blind, placebo-controlled, randomized study
    • Blersch W, Schulte-Mattler WJ, Przywara S, et al. 2002. Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J. Neurol. Sci. 205:59-63
    • (2002) J. Neurol. Sci. , vol.205 , pp. 59-63
    • Blersch, W.1    Schulte-Mattler, W.J.2    Przywara, S.3
  • 36
    • 0034603438 scopus 로고    scopus 로고
    • Presynaptic effects of botulinum toxin type a on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles
    • Ishikawa H, Mitsui Y, Yoshitomi T, et al. 2000. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn. J. Ophthalmol. 44:106-9
    • (2000) Jpn. J. Ophthalmol. , vol.44 , pp. 106-109
    • Ishikawa, H.1    Mitsui, Y.2    Yoshitomi, T.3
  • 37
    • 0033991246 scopus 로고    scopus 로고
    • Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins
    • Welch MJ, Purkiss JR, Foster KA. 2000. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38:245-58
    • (2000) Toxicon , vol.38 , pp. 245-258
    • Welch, M.J.1    Purkiss, J.R.2    Foster, K.A.3
  • 38
    • 0042392072 scopus 로고    scopus 로고
    • Mechanisms of the antinociceptive effect of subcutaneous Botox®: Inhibition of peripheral and central nociceptive processing
    • Abstr.
    • Cui M, Li Z, You S, et al. 2003. Mechanisms of the antinociceptive effect of subcutaneous Botox®: inhibition of peripheral and central nociceptive processing. Arch. Pharmacol. 365:33 (Abstr.)
    • (2003) Arch. Pharmacol. , vol.365 , pp. 33
    • Cui, M.1    Li, Z.2    You, S.3
  • 39
    • 0034651211 scopus 로고    scopus 로고
    • Uses of botulinum toxin injection in medicine today
    • Munchau A, Bhatia KP. 2000. Uses of botulinum toxin injection in medicine today. BMJ 320:165
    • (2000) BMJ , vol.320 , pp. 165
    • Munchau, A.1    Bhatia, K.P.2
  • 40
    • 0025010020 scopus 로고
    • Botulinum treatment of childhood strabismus
    • Scott AB, Magoon EH, McNeer KW, et al. 1990. Botulinum treatment of childhood strabismus. Ophthalmology 97:1434-38
    • (1990) Ophthalmology , vol.97 , pp. 1434-1438
    • Scott, A.B.1    Magoon, E.H.2    McNeer, K.W.3
  • 41
    • 0028569051 scopus 로고
    • Botulinum toxin in clinical practice
    • Hughes AJ. 1994. Botulinum toxin in clinical practice. Drugs 48:888-93
    • (1994) Drugs , vol.48 , pp. 888-893
    • Hughes, A.J.1
  • 43
    • 0036840028 scopus 로고    scopus 로고
    • A focused review on the use of botulinum toxins for neuropathic pain
    • Argoff CE 2002. A focused review on the use of botulinum toxins for neuropathic pain. Clin. J. Pain 6:S181
    • (2002) Clin. J. Pain , vol.6
    • Argoff, C.E.1
  • 44
    • 0036840844 scopus 로고    scopus 로고
    • A focused review of the use of botulinum toxins for low back pain
    • Difazio M, Jabbari B. 2002. A focused review of the use of botulinum toxins for low back pain. Clin. J. Pain 18:S155-S162
    • (2002) Clin. J. Pain , vol.18
    • Difazio, M.1    Jabbari, B.2
  • 45
    • 0036839955 scopus 로고    scopus 로고
    • Use of botulinum toxin in chronic whiplash-associated disorder
    • Freund BJ, Schwartz M. 2002. Use of botulinum toxin in chronic whiplash-associated disorder. Clin. J. Pain 18: S163-S168
    • (2002) Clin. J. Pain , vol.18
    • Freund, B.J.1    Schwartz, M.2
  • 46
    • 0036834143 scopus 로고    scopus 로고
    • Treatment of headache with botulinum toxin a - A review according to evidence-based medicine criteria
    • Evers S, Rahmann A, Vollmer-Haase J, et al. 2002. Treatment of headache with botulinum toxin A - a review according to evidence-based medicine criteria. Cephalalgia 22:699-710
    • (2002) Cephalalgia , vol.22 , pp. 699-710
    • Evers, S.1    Rahmann, A.2    Vollmer-Haase, J.3
  • 47
    • 0036840845 scopus 로고    scopus 로고
    • Use of botulinum toxins for chronic headaches: A focused review
    • Loder E, Biondi D. 2002. Use of botulinum toxins for chronic headaches: a focused review. Clin. J. Pain 18:S169-S176
    • (2002) Clin. J. Pain , vol.18
    • Loder, E.1    Biondi, D.2
  • 48
    • 0042369054 scopus 로고    scopus 로고
    • The use of botulinum toxin type a in headache treatment
    • Mathew NT, Kaup AO. 2002. The use of botulinum toxin type A in headache treatment Curr. Treatment Options Neurol. 4:365-73
    • (2002) Curr. Treatment Options Neurol. , vol.4 , pp. 365-373
    • Mathew, N.T.1    Kaup, A.O.2
  • 50
    • 0033668492 scopus 로고    scopus 로고
    • Botulinum toxin type a (Botox) for treatment of migraine headaches: An open-label study
    • Binder WJ, Brin MF, Blitzer A, et al. 2000. Botulinum toxin type A (Botox) for treatment of migraine headaches: an open-label study. Otolaryngol. Head Neck Surg. 123:669-76
    • (2000) Otolaryngol. Head Neck Surg. , vol.123 , pp. 669-676
    • Binder, W.J.1    Brin, M.F.2    Blitzer, A.3
  • 51
    • 0033917504 scopus 로고    scopus 로고
    • Botulinum toxin type a as a migraine preventive treatment
    • Silberstein SD, Mathew N, Saper J, et al. 2000. Botulinum toxin type A as a migraine preventive treatment. Headache 40:445-50
    • (2000) Headache , vol.40 , pp. 445-450
    • Silberstein, S.D.1    Mathew, N.2    Saper, J.3
  • 52
    • 0002661469 scopus 로고    scopus 로고
    • Botox for migraine: Double-blind, placebo-controlled, region-specific evaluation
    • Abstr.
    • Brin MF, Swope DM, O'Brien C, et al. 2000. Botox for migraine: double-blind, placebo-controlled, region-specific evaluation. Cephalalgia 20: 421 (Abstr.)
    • (2000) Cephalalgia , vol.20 , pp. 421
    • Brin, M.F.1    Swope, D.M.2    O'Brien, C.3
  • 53
    • 0038290443 scopus 로고    scopus 로고
    • Efficacy and safety of botulinum toxin type a (Botox®) in the prophylactic treatment of migraine
    • Abstr.
    • Barrientos N, Chana P. 2002. Efficacy and safety of botulinum toxin type A (Botox®) in the prophylactic treatment of migraine. Headache 42:452 (Abstr.)
    • (2002) Headache , vol.42 , pp. 452
    • Barrientos, N.1    Chana, P.2
  • 54
    • 0037952892 scopus 로고    scopus 로고
    • Single-site Botox injection for the elimination of migraine trigger points
    • Abstr.
    • Behmand RA, Tucker T, Guyuron B, et al. 2002. Single-site Botox injection for the elimination of migraine trigger points. Headache 42:403 (Abstr.)
    • (2002) Headache , vol.42 , pp. 403
    • Behmand, R.A.1    Tucker, T.2    Guyuron, B.3
  • 55
    • 0347335621 scopus 로고    scopus 로고
    • Botulinum toxin type-A reduces acute medication (triptans) use in migraine patients
    • Abstr.
    • Relja MA, Klepac N. 2003. Botulinum toxin type-A reduces acute medication (triptans) use in migraine patients. Neurology 60:A321 (Abstr.)
    • (2003) Neurology , vol.60
    • Relja, M.A.1    Klepac, N.2
  • 56
    • 0000338266 scopus 로고    scopus 로고
    • Botulinum toxin a is an effective prophylactic therapy for migraines
    • Abstr.
    • Mauskop A, Basdeo R. 2000. Botulinum toxin A is an effective prophylactic therapy for migraines. Cephalalgia 20:422 (Abstr.)
    • (2000) Cephalalgia , vol.20 , pp. 422
    • Mauskop, A.1    Basdeo, R.2
  • 57
    • 0000099456 scopus 로고    scopus 로고
    • Botulinum toxin type a in the treatment of headache syndromes: A clinical report on 79 patients
    • Abstr.
    • Smuts JA, Barnard PW. 2000. Botulinum toxin type A in the treatment of headache syndromes: a clinical report on 79 patients. Cephalalgia 20:332 (Abstr.)
    • (2000) Cephalalgia , vol.20 , pp. 332
    • Smuts, J.A.1    Barnard, P.W.2
  • 58
    • 0038211994 scopus 로고    scopus 로고
    • "Disease modification" in chronic migraine with botulinum toxin type A: Long-term experience
    • Abstr.
    • Mathew NT, Kailasam J, Meadors L. 2002. "Disease modification" in chronic migraine with botulinum toxin type A: long-term experience. Headache 42:454-( Abstr.)
    • (2002) Headache , vol.42 , pp. 454
    • Mathew, N.T.1    Kailasam, J.2    Meadors, L.3
  • 59
    • 1542276450 scopus 로고    scopus 로고
    • Botulinum toxin a for refractory chronic daily headache
    • Abstr.
    • Robbins LD. 2001. Botulinum toxin A for refractory chronic daily headache. Cephalalgia 21:465 (Abstr.)
    • (2001) Cephalalgia , vol.21 , pp. 465
    • Robbins, L.D.1
  • 60
    • 1542306590 scopus 로고    scopus 로고
    • Botulinum toxin a for chronic daily headache: A 60-patient, randomized, placebo-controlled, parallel design study
    • Abstr.
    • Ondo WG, Derman HS. 2002. Botulinum toxin A for chronic daily headache: a 60-patient, randomized, placebo-controlled, parallel design study. Headache 42:431 (Abstr.)
    • (2002) Headache , vol.42 , pp. 431
    • Ondo, W.G.1    Derman, H.S.2
  • 61
    • 0023857464 scopus 로고
    • Antitoxin reduces botulinum side effects
    • Scott AB. 1988. Antitoxin reduces botulinum side effects. Eye 2:29-32
    • (1988) Eye , vol.2 , pp. 29-32
    • Scott, A.B.1
  • 62
    • 0018799297 scopus 로고
    • Disorders of neuromuscular transmission caused by drugs
    • Argov Z, Mastaglia FL. 1979. Disorders of neuromuscular transmission caused by drugs. N. Engl J. Med. 301:409-13
    • (1979) N. Engl J. Med. , vol.301 , pp. 409-413
    • Argov, Z.1    Mastaglia, F.L.2
  • 63
    • 85031061407 scopus 로고    scopus 로고
    • Botulinum toxin type B for migraine prophylaxis: A 4-month open-label prospective outcome study
    • Abstr.
    • Lake AE, Saper JR. 2003. Botulinum toxin type B for migraine prophylaxis: a 4-month open-label prospective outcome study. Neurology 60:A322 (Abstr.)
    • (2003) Neurology , vol.60
    • Lake, A.E.1    Saper, J.R.2
  • 64
    • 0011140951 scopus 로고    scopus 로고
    • Open-label study of Myobloc (botulinum toxin type B) in the treatment of patients with transformed migraine headaches
    • Abstr.
    • Opida C. 2002. Open-label study of Myobloc (botulinum toxin type B) in the treatment of patients with transformed migraine headaches. J. Pain 3:10 (Abstr.)
    • (2002) J. Pain , vol.3 , pp. 10
    • Opida, C.1
  • 65
    • 26144480416 scopus 로고    scopus 로고
    • Double-blind, placebo-controlled study of botulinum toxin B for the treatment of chronic headache
    • Abstr.
    • Gwynn MW, Baker T, English J. 2003. Double-blind, placebo-controlled study of botulinum toxin B for the treatment of chronic headache. Neurology 60:A322 (Abstr.)
    • (2003) Neurology , vol.60
    • Gwynn, M.W.1    Baker, T.2    English, J.3
  • 67
    • 0030710582 scopus 로고    scopus 로고
    • Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy
    • Langtry HD, Gillis JC, Davis R. 1997. Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 54:752-73
    • (1997) Drugs , vol.54 , pp. 752-773
    • Langtry, H.D.1    Gillis, J.C.2    Davis, R.3
  • 69
    • 0032171131 scopus 로고    scopus 로고
    • Use of topiramate, a new antiepileptic as a mood stabilizer
    • Marcotte D. 1998. Use of topiramate, a new antiepileptic as a mood stabilizer. J. Affect. Disord. 50:245-51
    • (1998) J. Affect. Disord. , vol.50 , pp. 245-251
    • Marcotte, D.1
  • 70
    • 1542366353 scopus 로고    scopus 로고
    • Efficacy and safety of topiramate in migraine prevention: A dose ranging placebo-controlled, double blind, multi-centered trial
    • In press
    • Silberstein SD, Neto W, Jacobs D, et al. 2003. Efficacy and safety of topiramate in migraine prevention: a dose ranging placebo-controlled, double blind, multi-centered trial. Cephalalgia In press
    • (2003) Cephalalgia
    • Silberstein, S.D.1    Neto, W.2    Jacobs, D.3
  • 71
    • 0035654407 scopus 로고    scopus 로고
    • Antiepileptic drugs: How they work in headache
    • Cutrer FM. 2001. Antiepileptic drugs: how they work in headache. Headache 41(Suppl. 1):S3-S10
    • (2001) Headache , vol.41 , Issue.1 SUPPL.
    • Cutrer, F.M.1
  • 72
    • 0344809172 scopus 로고    scopus 로고
    • Topiramate inhibits trigeminovascular traffic in the cat: A possible locus of action in the prevention of migraine
    • Abstr.
    • Storer RJ, Goadsby PJ. 2003. Topiramate inhibits trigeminovascular traffic in the cat: a possible locus of action in the prevention of migraine. Neurology 60:A238 (Abstr.)
    • (2003) Neurology , vol.60
    • Storer, R.J.1    Goadsby, P.J.2
  • 73
    • 0036781473 scopus 로고    scopus 로고
    • Topiramate: A case series study in migraine prophylaxis
    • Young WB, Hopkins MM, Shechter AL, et al. 2002. Topiramate: a case series study in migraine prophylaxis. Cephalalgia 22:659-63
    • (2002) Cephalalgia , vol.22 , pp. 659-663
    • Young, W.B.1    Hopkins, M.M.2    Shechter, A.L.3
  • 74
    • 0036754793 scopus 로고    scopus 로고
    • Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate
    • Mathew NT, Kailasam J, Meadors L. 2002. Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate. Headache 42:796-803
    • (2002) Headache , vol.42 , pp. 796-803
    • Mathew, N.T.1    Kailasam, J.2    Meadors, L.3
  • 75
    • 0344809171 scopus 로고    scopus 로고
    • Topiramate in the prevention of migraine headache: A randomized, double-blind, placebo-controlled, multiple-dose study
    • In press
    • Silberstein SD, Bhattacharaya S, Neto W, et al., for the MIGR-001 Study Group. 2003. Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled, multiple-dose study. Cephalagia In press
    • (2003) Cephalagia
    • Silberstein, S.D.1    Bhattacharaya, S.2    Neto, W.3
  • 76
    • 0038762226 scopus 로고    scopus 로고
    • Topiramate in the prevention of migraine headache: A randomized, double-blind, placebo-controlled parallel study (MIGR-002)
    • Abstr.
    • Brandes JL, Jacobs D, Neto W, et al. 2003. Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled parallel study (MIGR-002). Neurology 60(Suppl. 1):A238 (Abstr.)
    • (2003) Neurology , vol.60 , Issue.1 SUPPL.
    • Brandes, J.L.1    Jacobs, D.2    Neto, W.3
  • 77
    • 0035651241 scopus 로고    scopus 로고
    • Topiramate in migraine prevention: A double-blind, placebo-controlled study
    • Storey JR, Calder CS, Hart DE, et al. 2001. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 41:968-75
    • (2001) Headache , vol.41 , pp. 968-975
    • Storey, J.R.1    Calder, C.S.2    Hart, D.E.3
  • 78
    • 0036754584 scopus 로고    scopus 로고
    • Efficacy of topiramate in migraine prophylaxis: A retrospective chart analysis
    • Von Seggern RL, Mannix LK, Adelman JU. 2002. Efficacy of topiramate in migraine prophylaxis: a retrospective chart analysis. Headache 42:804-9
    • (2002) Headache , vol.42 , pp. 804-809
    • Von Seggern, R.L.1    Mannix, L.K.2    Adelman, J.U.3
  • 79
    • 0029164712 scopus 로고
    • ACE inhibitors for prophylaxis of migraine headaches
    • Bender WI. 1995. ACE inhibitors for prophylaxis of migraine headaches. Headache 35:470-71
    • (1995) Headache , vol.35 , pp. 470-471
    • Bender, W.I.1
  • 80
    • 0035814597 scopus 로고    scopus 로고
    • Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): Randomised, placebo-controlled, crossover study
    • Schrader H, Stovner LJ, Helde G, et al. 2001. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo-controlled, crossover study. Br. J. Med. Psychol. 3222:19-22
    • (2001) Br. J. Med. Psychol. , vol.3222 , pp. 19-22
    • Schrader, H.1    Stovner, L.J.2    Helde, G.3
  • 81
    • 0037218941 scopus 로고    scopus 로고
    • Prophylactic treatment of migraine with an angiotensin II receptor blocker a randomized controlled trial
    • Tronvik E, Stovner LJ, Helde G, et al. 2003. Prophylactic treatment of migraine with an angiotensin II receptor blocker a randomized controlled trial. JAMA 289:65-69
    • (2003) JAMA , vol.289 , pp. 65-69
    • Tronvik, E.1    Stovner, L.J.2    Helde, G.3
  • 82
    • 0033796377 scopus 로고    scopus 로고
    • 1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats
    • 1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 31:2478-86
    • (2000) Stroke , vol.31 , pp. 2478-2486
    • Nishimura, Y.1    Ito, T.2    Saavedra, J.M.3
  • 83
    • 0027156129 scopus 로고
    • Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats
    • Mendelsohn FA, Jenkins TA, Berkovic SF. 1993. Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats. Brain Res. 613:221-29
    • (1993) Brain Res. , vol.613 , pp. 221-229
    • Mendelsohn, F.A.1    Jenkins, T.A.2    Berkovic, S.F.3
  • 84
    • 0036322902 scopus 로고    scopus 로고
    • Locally synthesized angiotensin modulates pineal melatonin generation
    • Baltatu O, Afeche SC, Jose-dos Santos SH, et al. 2002. Locally synthesized angiotensin modulates pineal melatonin generation. J. Neurochem. 80:328-34
    • (2002) J. Neurochem. , vol.80 , pp. 328-334
    • Baltatu, O.1    Afeche, S.C.2    Jose-Dos Santos, S.H.3
  • 85
    • 0036009156 scopus 로고    scopus 로고
    • Nuclear factor-κB as a molecular target for migraine therapy
    • Reuter U, Chiarugi A, Bolay H, et al. 2002. Nuclear factor-κB as a molecular target for migraine therapy. Ann. Neurol. 51:507-16
    • (2002) Ann. Neurol. , vol.51 , pp. 507-516
    • Reuter, U.1    Chiarugi, A.2    Bolay, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.